May 11, 2026

Dyslipidaemia (11 May 2026)

Dyslipidaemia (11 May 2026)
Dyslipidaemia (11 May 2026)
Clinical Conversations
Dyslipidaemia (11 May 2026)
Soundcloud podcast player badge
Spotify podcast player badge
Apple Podcasts podcast player badge
Youtube Music podcast player badge
Castro podcast player badge
RSS Feed podcast player badge
Soundcloud podcast player iconSpotify podcast player iconApple Podcasts podcast player iconYoutube Music podcast player iconCastro podcast player iconRSS Feed podcast player icon
In this episode, Dr Angus Sinclair speaks with Dr Jonathan Malo about dyslipidaemias. They discuss the different types of dyslipidaemias, the treatments (including some new ones) and the types of cases that should be referred. Dr Jonathan Malo is a consultant chemical pathologist at the Department of Clinical Biochemistry in NHS Lothian. And is the clinical lead for the Lipid Clinic at the Royal Infirmary of Edinburgh. He currently chairs a Scottish network of lipid clinic specialists, and is involved in a Scottish government group tasked with improving CVD prevention. Dr Angus Sinclair is an Internal Medical Trainee in the East of Scotland. He graduated from the University of Edinburgh in 2018 and since then has worked across Scotland and as a medical registrar in a rural district general hospital in New Zealand. He has been actively involved in undergraduate and postgraduate teaching, as well as in clinical governance and resident doctor leadership. Recording date: 20 March 2026 --Links-- Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials, The Lancet, 2026; 407, 689-703. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials, The Lancet, 2022; 400, 832-845. N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects, NEJM, 2020;383:2182-2184. DOI: 10.1056/NEJMc2031173. Statin treatment and muscle symptoms: series of randomised, placebo-controlled n-of-1 trials. BMJ, 2021;372:n135. https://doi.org/10.1136/bmj.n135 SIGN 149: Risk estimation and the prevention of cardiovascular disease (2017) - https://www.sign.ac.uk/assets/qrg149.pdf NICE Guideline 238: Cardiovascular disease: risk assessment and reduction, including lipid modification (2023) - https://www.nice.org.uk/guidance/ng238/resources/cardiovascular-disease-risk-assessment-and-reduction-including-lipid-modification-pdf-66143902851781) AHA guideline - https://www.ahajournals.org/doi/10.1161/CIR.0000000000001423 ASSIGN/QRISK score calculators - https://www.heartuk.org.uk/educational-content/risk-calculators -- Follow us -- https://www.instagram.com/rcpedintrainees -- Upcoming RCPE events -- https://www.rcpe.ac.uk/events -- Become an RCPE Member -- https://www.rcpe.ac.uk/membership/join-college Feedback: cme@rcpe.ac.uk This podcast is from the Trainees & Members' Committee (T&MC) of the Royal College of Physicians of Edinburgh (RCPE).

Follow us

RCPE T&MC Instagram


Upcoming RCPE events

RCPE Events


Become an RCPE Member

Join RCPE


Feedback

cme@rcpe.ac.uk


This podcast is from the Trainees & Members' Committee (T&MC) of the Royal College of Physicians of Edinburgh (RCPE).